DONA →

Ensayo clínico NCT03600701 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma

Portada editorial de Strongers para el estudio clínico NCT03600701 (Fase II), estado: activo, sin reclutamiento — Recurrent Lung Non-Small Cell Carcinoma.
Investigación oncológica 16/11/2026

NCT03600701 — figura como «activo (sin reclutamiento)» en ClinicalTrials.gov.

Ensayo clínico NCT03600701 (fase II) figura como «activo (sin reclutamiento)» en ClinicalTrials.gov.

Patología: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma · Intervenciones registradas: Atezolizumab, Cobimetinib · Fechas registradas (fuente): 2018-11-29, 2025-07-14, 2018-07-26, 2026-11-13.

Resumen del estudio (fuente: ClinicalTrials.gov, texto original en inglés):

This phase II trial studies how well atezolizumab and cobimetinib work in treating patients with non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic), has come back (recurrent), or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cobimetinib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving atezolizumab and cobimetinib may work better in treating patients with non-small cell lung cancer.

Fuente: https://clinicaltrials.gov/study/NCT03600701

Una newsletter para quienes compiten, donan y creen en la investigación

Eventos, becas asignadas, historias de quienes hacen posible la investigación. Un email al mes, sin spam.